Results 241 to 250 of about 112,622 (301)

[Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice]. [PDF]

Aktuelle Urol
Retz M, Borkowetz A, Wittenzellner K, Aga-Barfknecht H, von Amsberg G.   +4 more
europepmc   +1 more source

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Germline pathogenic variants can inform targeted therapy for metastatic prostate cancer (mPC), and improve cancer early detection and risk reduction for family members. Guidelines recommend germline genetic testing be offered to all men with mPC, yet uptake of testing is only 10%–12%. Methods This prospective study enrolled veterans
Bruce Montgomery, Julie A. Lynch, Jessica Brown, Kara N. Maxwell, Craig C. Teerlink, Nismeta Kabilovic, Katie Stoll, Julie Simon, Maria Kogan, Sajida Hassan, Stacey B. Whitbourne, Sumitra Muralidhar, Martin W. Schoen, Rachel Ramoni, J. Michael Gaziano, Alexandra O. Sokolova, Heather H. Cheng, Ruth Etzioni, Colin C. Pritchard   +18 more
wiley   +1 more source

Triple Negative Breast Cancer With Choroidal Metastasis Responsive to Sacituzumab Govitecan and Radiation Therapy

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Orbital metastases are rare in patients with breast cancer. However, medical management of orbital metastases is limited by the inability of treatment options to penetrate the blood‐brain barrier. In patients with triple negative breast cancer (TNBC), these treatment options are further limited.
Nellie Nafissi, Aditya Mahadevan, Elaine Chiao, Nejina Rijal, Ritesh Parajuli   +4 more
wiley   +1 more source

CEACAM6 silencing suppresses tumour growth and sensitises cholangiocarcinoma to cisplatin

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
CEACAM6 has the potential to become a novel and independent prognostic biomarker in cholangiocarcinoma (CCA). Silencing CEACAM6 can inhibit CCA tumour growth and significantly enhance the chemosensitivity to cisplatin. This chemo‐sensitising effect is mediated through the disruption of ribosome biogenesis and impairment of DNA damage repair.
Shi‐Jia Dai, Jiang‐Qi Tan, Jia‐Qi Guo, Ya‐Nan Zhou, Teng Huang, Hao‐Lin Jiang, Yang Liu, Li‐Wei Dong, Zhen‐Gang Yuan   +8 more
wiley   +1 more source

5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells. [PDF]

J Biol Chem
Kharat SS, Mishra AP, Sengodan SK, Dierman D, Fox SD, Chazin WJ, Sharan SK.   +6 more
europepmc   +1 more source

DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu, Yuzhu Ma, Yueying Gao, Yao Chen, Xinyu Li, Yue Wu, Meiling Sun, Qizhao Li, Yanhong Zhao, Shuqian Xu, Shengjin Fan, Yongsheng Li, Huitao Fan   +12 more
wiley   +1 more source

PARP inhibitor BMN673 triggers PARylation-mediated ATF4-GDF15 pathway to drive autophagy and ferroptosis in ataxia telangiectasia mutated gene-deficient colorectal cancer cells. [PDF]

Mol Biomed
Xiang J, Xu J, Fan H, Chen Q, Lu Y, Wan X, Jiang Y, Zhang X, Zhang C, Liu Q, Ding D, Lei Y.   +11 more
europepmc   +1 more source

Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This graphical abstract illustrates the role of KMT2C loss‐of‐function in promoting breast cancer progression and therapeutic vulnerability. KMT2C deficiency drives tumor heterogeneity, metastasis, and therapy resistance by activating oncogenic pathways such as IFNγEMT/MET and MAPK/ERKRAS/PI3K/AKT/mTOR, along with epigenetic remodeling via the ...
Shuangmei Tong, Qiu Wang, Yun Chen, Zunjie Bo, Ya Zhang, Yan Liu   +5 more
wiley   +1 more source

Protocol for quantifying PARP inhibitor-induced changes in PARP1 dynamics and activity through live-cell imaging. [PDF]

STAR Protoc
Kanev PB, Varhoshkova S, Aleksandrov A, Stoynov S, Aleksandrov R.   +4 more
europepmc   +1 more source

Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor-Insensitive Breast Cancer Cells. [PDF]

Cancer Sci
Muraoka H, Kazuno H, Hashimoto A, Sootome H, Ohkubo S.   +4 more
europepmc   +1 more source